Monday, December 1 | 3:40 p.m.-3:50 p.m. | M7-SSNMMI03-5 | Room S501
Lutetium-177 prostate-specific membrane antigen-617 (Lu-177 PSMA-617) benefits patients with metastatic castration-resistant prostate cancer (mCRPC), but individual outcomes vary.
Presenter Yalda Nikanpour, MD, a postdoctoral research fellow at the Mayo Clinic in Rochester, MN, and colleagues, found that quantitative post-therapy SPECT/CT can identify patients at higher risk of poor outcomes.
The researchers analyzed post-therapy whole-body SPECT/CT imaging performed 24 hours after each infusion among 50 patients with mCRPC. Five patients received four cycles, 12 received five cycles, and 33 completed six cycles of therapy, with a mean overall survival (OS) for the cohort of 24.7 months.
Quantitative changes in tumor burden on SPECT/CT were associated with OS, particularly at cycles four and five, according to the findings. The strongest association was observed at cycle four, in which change in lesion uptake volume product (UVP) from baseline was linked to predicted survival (hazard ratio [HR] 3.1, p = 0.0009).
In addition, total lesion volume changes from baseline to cycles four and five also reached significance (HR 2, p = 0.009), while maximum lesion standardized uptake value was predictive only at cycle five (HR 1.7, p = 0.019).
“Change in tumor burden quantified on post-therapy SPECT/CT during Lu-177 PSMA treatment predicted OS in patients with mCRPC,” the group concluded.
Attend this session to learn how the findings may support early response evaluation in mCRPC.